Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company is headquartered in Tianjin, Tianjin and currently employs 86 full-time employees. The company went IPO on 2006-05-23. The Company’s main business is engaged in producing and distributing Reconstituted Bone Xenograft (RBX). The RBX is a medical device that accelerates bone healing. The firm distributes its medical devices to hospitals as well as other medical device customers that are not hospitals.
Genex Pharmaceutical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Genex Pharmaceutical Inc 주요 수익원은 American Performance이며, 최신 수익 발표에서 수익은 393,929,000입니다. 지역별로는 United States이 Genex Pharmaceutical Inc의 주요 시장이며, 수익은 597,999,000입니다.
Genex Pharmaceutical Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Genex Pharmaceutical Inc의 순손실은 $0입니다.